Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Glioma × Palonosetron × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Vomiting 33 Nausea 22 Neoplasms 11 Breast Neoplasms 6 Lymphoma 3 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Rectal Neoplasms 2 Multiple Myeloma 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Breast Neoplasms, Male 2 Weight Loss 1 Solid Tumors 1 Sarcoma 1 Radiation Injuries 1 Pancreatic Neoplasms 1 Neoplasms, Germ Cell and Embryonal 1 Nausea With Vomiting Chemotherapy-Induced 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Liver Neoplasms 1 Leukemia 1 Inflammatory Breast Neoplasms 1 Hematologic Neoplasms 1 Glioma 1 Genital Neoplasms, Female 1 Gastrointestinal Neoplasms 1 Gallbladder Neoplasms 1

Interventions

Temozolomide 143 Bevacizumab 63 Radiotherapy 60 Magnetic Resonance Spectroscopy 58 Irinotecan 27 Carboplatin 23 Surgical Procedures, Operative 22 Radiation 19 Carmustine 18 Aminolevulinic Acid 18 Specimen Handling 17 Nivolumab 16 Blood Specimen Collection 16 Lomustine 15 Biopsy 15 pembrolizumab 13 Radiotherapy, Intensity-Modulated 12 Cyclophosphamide 12 trametinib 11 Topotecan 11 Radiosurgery 11 Erlotinib Hydrochloride 11 fluorodopa F 18 10 X-Rays 10 IL13-PE38 9 Everolimus 9 ribociclib 8 dabrafenib 8 Surveys and Questionnaires 8 Magnetic Resonance Imaging 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00900757 2019-08-28

Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide

Duke University

Phase 2 Completed

57 enrolled 10 charts

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡